Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Opgen Inc (NQ: OPGN )

0.2427 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Opgen Inc

< Previous 1 2 Next >
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
From OpGen, Inc.
Via GlobeNewswire
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
From OpGen, Inc.
Via GlobeNewswire
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
From OpGen, Inc.
Via GlobeNewswire
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
From OpGen, Inc.
Via GlobeNewswire
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
From OpGen, Inc.
Via GlobeNewswire
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
From OpGen, Inc.
Via GlobeNewswire
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
From OpGen, Inc.
Via GlobeNewswire
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
From OpGen, Inc.
Via GlobeNewswire
OpGen Announces Closing of $3.5 Million Public Offering
From OpGen, Inc.
Via GlobeNewswire
OpGen Announces Pricing of $3.5 Million Public Offering
From OpGen, Inc.
Via GlobeNewswire
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
From OpGen, Inc.
Via GlobeNewswire
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
From OpGen, Inc.
Via GlobeNewswire
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
From OpGen, Inc.
Via GlobeNewswire
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
From OpGen, Inc.
Via GlobeNewswire
OpGen’s Subsidiary Curetis Meets Milestones in Collaborative Research Project with InfectoGnostics
From OpGen, Inc.
Via GlobeNewswire
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From OpGen, Inc.
Via GlobeNewswire
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
From OpGen, Inc.
Via GlobeNewswire
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
From OpGen, Inc.
Via GlobeNewswire
OpGen Announces Exercise of All Prefunded Warrants
From OpGen, Inc.
Via GlobeNewswire
OpGen subsidiary Ares Genetics announces granting of key patent in China
From OpGen, Inc.
Via GlobeNewswire
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
From OpGen, Inc.
Via GlobeNewswire
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
Successful delivery of milestones triggers milestone payment 
From OpGen, Inc.
Via GlobeNewswire
OpGen Announces Closing of $7.5 Million Public Offering
From OpGen, Inc.
Via GlobeNewswire
OpGen Announces Pricing of $7.5 Million Public Offering
From OpGen, Inc.
Via GlobeNewswire
OpGen Announced 1-for-20 Reverse Stock Split
From OpGen, Inc.
Via GlobeNewswire
OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI
OpGen, Inc. (NASDAQ: OPGN) is engaged as a precision medicine company that is focused on developing molecular diagnostics and bioinformatics 
Via Spotlight Growth
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
From OpGen, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.